CellCentric

CellCentric raised $220m in a Series D on 5 May 2026, reported by BioSpace as the largest private biotech financing in Europe in 2026. The round was led by Venrock Healthcare Capital Partners with Fidelity Management and Research, Sofinnova Partners, HBM Healthcare, RA Capital, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society BrightEdge initiative. No UK public investor participated, making it the largest UK biotech round of 2026 funded entirely by private and transatlantic capital.

The capital funds the Phase 2 DOMMINO-1 trial of inobrodib, CellCentric's oral p300/CBP inhibitor for relapsed and refractory multiple myeloma, running across the UK and US. Phase 3 DOMMINO-2 is planned for H2 2026. inobrodib targets the p300 and CBP epigenetic regulators, which multiple myeloma cells exploit to suppress anti-tumour gene expression; oral administration and an epigenetic mechanism make it a differentiated candidate in a market where novel combinations are sought for patients whose disease has progressed on standard regimens.

The absence of BBB or SAIU participation in Europe's largest 2026 biotech round is notable: it shows UK-headquartered companies can access US-scale capital without government anchoring, while also prompting questions about whether sovereign investment capacity is being deployed selectively.